MX2012008419A - Improved composition based on terpenoids and chloretone, and the use thereof in nasal items. - Google Patents
Improved composition based on terpenoids and chloretone, and the use thereof in nasal items.Info
- Publication number
- MX2012008419A MX2012008419A MX2012008419A MX2012008419A MX2012008419A MX 2012008419 A MX2012008419 A MX 2012008419A MX 2012008419 A MX2012008419 A MX 2012008419A MX 2012008419 A MX2012008419 A MX 2012008419A MX 2012008419 A MX2012008419 A MX 2012008419A
- Authority
- MX
- Mexico
- Prior art keywords
- nasal
- composition
- improved
- oil
- decongestant
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 229960004926 chlorobutanol Drugs 0.000 title claims abstract description 35
- 230000001976 improved effect Effects 0.000 title claims abstract description 25
- 150000003505 terpenes Chemical class 0.000 title claims abstract description 25
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims abstract description 26
- 241000723346 Cinnamomum camphora Species 0.000 claims abstract description 25
- 229960000846 camphor Drugs 0.000 claims abstract description 25
- 229930008380 camphor Natural products 0.000 claims abstract description 25
- 239000003921 oil Substances 0.000 claims abstract description 25
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 23
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229940041616 menthol Drugs 0.000 claims abstract description 23
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 18
- 239000006196 drop Substances 0.000 claims abstract description 17
- 239000007788 liquid Substances 0.000 claims abstract description 14
- 206010039083 rhinitis Diseases 0.000 claims abstract description 12
- 201000009890 sinusitis Diseases 0.000 claims abstract description 11
- 239000007921 spray Substances 0.000 claims abstract description 11
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 9
- 230000007815 allergy Effects 0.000 claims abstract description 9
- 239000002480 mineral oil Substances 0.000 claims abstract description 8
- 235000010446 mineral oil Nutrition 0.000 claims abstract description 8
- 229940099259 vaseline Drugs 0.000 claims abstract description 3
- 244000166124 Eucalyptus globulus Species 0.000 claims abstract 5
- 235000019198 oils Nutrition 0.000 claims description 24
- 230000001387 anti-histamine Effects 0.000 claims description 21
- 239000000133 nasal decongestant Substances 0.000 claims description 15
- 239000000739 antihistaminic agent Substances 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 13
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 12
- 235000019489 Almond oil Nutrition 0.000 claims description 10
- 239000008168 almond oil Substances 0.000 claims description 10
- 239000000341 volatile oil Substances 0.000 claims description 9
- 208000026935 allergic disease Diseases 0.000 claims description 8
- 208000023504 respiratory system disease Diseases 0.000 claims description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- 235000019271 petrolatum Nutrition 0.000 claims description 6
- 239000004264 Petrolatum Substances 0.000 claims description 5
- 229940066842 petrolatum Drugs 0.000 claims description 5
- 238000002663 nebulization Methods 0.000 claims description 3
- -1 chloretone (chlorobutanol) Chemical compound 0.000 claims description 2
- 230000001815 facial effect Effects 0.000 claims description 2
- 241000723347 Cinnamomum Species 0.000 claims 4
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract description 16
- 244000144725 Amygdalus communis Species 0.000 abstract 1
- 235000011437 Amygdalus communis Nutrition 0.000 abstract 1
- 235000020224 almond Nutrition 0.000 abstract 1
- 210000003928 nasal cavity Anatomy 0.000 description 15
- 244000004281 Eucalyptus maculata Species 0.000 description 13
- 239000000314 lubricant Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 239000003570 air Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 230000035807 sensation Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000002421 anti-septic effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003172 expectorant agent Substances 0.000 description 4
- 230000003419 expectorant effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000219927 Eucalyptus Species 0.000 description 3
- 206010028735 Nasal congestion Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000622 irritating effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 210000001132 alveolar macrophage Anatomy 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 230000002026 carminative effect Effects 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 230000000420 mucociliary effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- OOCCDEMITAIZTP-QPJJXVBHSA-N (E)-cinnamyl alcohol Chemical compound OC\C=C\C1=CC=CC=C1 OOCCDEMITAIZTP-QPJJXVBHSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- DSSYKIVIOFKYAU-OIBJUYFYSA-N (S)-camphor Chemical compound C1C[C@]2(C)C(=O)C[C@H]1C2(C)C DSSYKIVIOFKYAU-OIBJUYFYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- DJIOGHZNVKFYHH-UHFFFAOYSA-N 2-hexadecylpyridine Chemical compound CCCCCCCCCCCCCCCCC1=CC=CC=N1 DJIOGHZNVKFYHH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 208000027775 Bronchopulmonary disease Diseases 0.000 description 1
- KKVZAVRSVHUSPL-GQCTYLIASA-N Cassiastearoptene Chemical compound COC1=CC=CC=C1\C=C\C=O KKVZAVRSVHUSPL-GQCTYLIASA-N 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000021512 Cinnamomum verum Nutrition 0.000 description 1
- 235000004310 Cinnamomum zeylanicum Nutrition 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 239000001293 FEMA 3089 Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 241000282375 Herpestidae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- 208000030880 Nose disease Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- 206010070488 Upper-airway cough syndrome Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- OOCCDEMITAIZTP-UHFFFAOYSA-N allylic benzylic alcohol Natural products OCC=CC1=CC=CC=C1 OOCCDEMITAIZTP-UHFFFAOYSA-N 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- 125000002871 cinnamic aldehydes group Chemical group 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- BBEJNBLSSWFDSN-UHFFFAOYSA-N methylamino benzoate Chemical compound CNOC(=O)C1=CC=CC=C1 BBEJNBLSSWFDSN-UHFFFAOYSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- KKVZAVRSVHUSPL-UHFFFAOYSA-N o-methoxycinnamic aldehyde Natural products COC1=CC=CC=C1C=CC=O KKVZAVRSVHUSPL-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention refers to an improved nasal composition for treating rhinitis, nasal allergies, and sinusitis presented in a spray, drop or liquid form. The composition of the present invention comprises a terpenoid, chloretone (chlorobutanol), menthol, mineral oil, cinnamon and eucalyptus. The selected terpenoid to be used in the composition is camphor. The mineral oil selected is Vaseline and/or natural oil of almond and/or mixtures thereof.
Description
AN IMPROVED COMPOSITION BASED ON A TERPENOID AND CHLORETONE IN ADDITION TO ITS USE IN NASAL ARTICLES
Field of the invention
The present invention relates to an improved nasal composition for use against rhinitis, nasal allergy, sinusitis in the form of spray, drops, liquid, face towels or disposable handkerchief. The composition of the present invention comprises a terpenoid, a chloretone (chlorobutanol), menthol, mineral and / or natural oil, cinnamon and eucalyptus. The terpenoid selected for use in the composition of the present invention is camphor. The mineral and / or natural oil is selected from petrolatum and / or almond oil and / or mixtures thereof.
The main purpose of the present invention is to prepare a composition for use against nasal diseases, causing a refreshing sensation that allows greater ease of breathing, causing a lower sensation of nasal congestion.
Anteceden-be of the invention
In the present there are several useful products for the treatment of respiratory congestive diseases. Generally the pharmaceutical compositions contain drugs and combinations thereof that serve
these sufferings. However, sometimes they are not able to correctly treat the different symptoms that may be associated with a respiratory tract disease such as seasonal allergic rhinitis, permanent allergic rhinitis, common colds, sinusitis and concomitant symptoms associated with these types. of diseases or allergic asthma. Symptoms of these diseases can include nasal congestion, sneezing, runny and itchy nose, redness of the eyes, tearing, itching of the ears or palate and cough associated with postnasal drip.
The respiratory system, like the digestive tract, offers a wide contact surface with the external environment and therefore is exposed to the harmful influences of the. environment through a multiplicity of inert and biological elements, such as dust, irritating gases, temperature and extreme humidity, viruses, bacteria, parasites and fungi.
Among the existing patent documents relating to the use of a nasal composition for the treatment of respiratory diseases is patent application RU2288757 which relates to a composition for the treatment of diseases of the oral and nasal cavities comprising active components such as chlorobutanol hydrate, essential oils, camphor and menthol in equal proportions, petrolatum, emulsifier "Tverdy-2" and "Tween-80" as a carrier and water in which the components in a defined amount.
JP2004339213 (A) discloses nasal drops containing one or more species selected from flunisolide, beclomethasone, and its derivatives, one or more species selected from the group consisting of menthol, camphor, borneol and geraniol and one or more species from the group it consists of chlorobutanol, lidocaine, dibucaine, procaine, procainamide and methyl aminobenzoate furthermore it contains a viscosifier such as propylene glycol alginate and the like.
Patent document JP2001247446 A discloses a cleaning agent capable of easily cleaning the oral internal cavity or the internal nasal cavity, composed of seawater and an active ingredient such as cetylpyridin chloride, benzethonium chloride, benzalkonium chloride, zinc sulfate, menthol, camphor, fennel oil, peppermint oil, clove oil, cinnamon oil or the like.
These documents and others existing in the prior art do not disclose the improved composition of the present invention, especially due to the fact that in the present invention menthol, chlorobutanol, camphor, cinnamon, eucalyptus with mineral oil are combined in a proportion that provides a surprisingly improved effect.
Therefore, it is considered that the present invention is new and inventive with respect to the previous documents, besides solving a serious problem and having advantages with the existing compositions and procedures since it surprisingly confers a refreshing effect and sensation
that allows easier breathing. causing less sensation of nasal congestion.
DESCRIPTION OF THE INVENTION
The present invention relates to an improved nasal composition for use against rhinitis, nasal allergy, sinusitis in the form of spray, drops, liquid, face towels or disposable handkerchief.
Bronchopulmonary diseases are usually established by the action of a multiplicity of associated factors. It is difficult to attribute a lung pathological state to a single agent, but rather to a synergistic effect of two or more of them.
Some of the factors that can alter the defense mechanisms, or that favor the establishment of infectious agents, are those detailed below:
-Anatomics: The respiratory apparatus offers a surface widely open to the external environment; young individuals are the ones with greater susceptibility, since they have a shorter and immature respiratory tract than adults. Among the animal species, it is the pigs and cattle that usually suffer pulmonary diseases, due to the presence
of an accessory bronchus that goes directly to the apical lobe of the lung.
-Epidemiological: in domestic animals, respiratory diseases show a marked enzootic character, in the form of frequent outbreaks, whose favorite target are young individuals and especially those kept in confinement and in large concentrations. The main management elements that may contribute to the development of enzootic infectious bronchopneumonia are listed below. Some of these characteristics are valid also for human beings.
-The thermal variations: Cooling causes ischemia of the mucosa and this reduces the filtration and purification of the inspired air. The heating produces hyperactivity of the vibrating cilia, functional exhaustion and corrosion of the mucociliary apparatus. Therefore, although respiratory diseases are more frequent during the winter due to the cold, it is not uncommon to observe sporadic pictures in areas with very warm winds, or when people stay for long periods of time in heated environments. exaggerated
-The hygrometric variations: The elevation of the hygrometric degree reinforces the action of cold, decreases the production of secretory Immunoglobulin A and the activity of alveolar macrophages. Drying the ambient air increases the viscosity of the bronchial mucus and causes paralysis
of the mucociliary Hot air also contributes to that same desiccation.
-The increase of chemical pollution of the environmental air: The accumulation of gases, ammonia in particular, produces functional disorders and severe injuries of the defensive apparatus. Repeated contact with them, as occurs in certain industries or laboratories, causes permanent damage to the epithelium of the respiratory tract, causing irreversible transformation of the cells, a phenomenon known as squamous metaplasia. The same effect is generated by cigarette smoke in smokers.
-The increase of the biological pollution of the environmental air: The inhalation of living particles (microorganisms) or inerts (powders) in excessive quantity, exceeds the means of mechanical, biochemical and immunological defense. Pulmonary macrophages phagocytose foreign particles, but they can rarely get rid of those inerts such as soot, so even if they do not die, they lose their capacity for phagocytosis, and in addition to this, their non-disappearance does not stimulate their replacement, so the capacity The overall response of the lung to pathogens decreases.
Diseases of the respiratory system, both of animals and humans, is very influenced by the environment. To these climatic influences are added the
breeding conditions, feeding and various pathogens present in the environment.
The present invention provides an improved nasal composition for use against rhinitis, nasal allergy, sinusitis and other respiratory diseases.
The composition of the present invention comprises a terpenoid, chloretone (chlorobutanol), menthol, mineral and / or natual oil, cinnamon and eucalyptus. The terpenoid selected for use in the composition is camphor.
The composition of the present invention comprises 12 to 22% of a terpenoid, 9 to 20% of chloretone (chlorobutanol), 15 to 30% of menthol, 25 to 35% mineral and / or natural oil, 0.001 to 2% of cinnamon and 7 to 18% of eucalyptus. The terpenoid selected for use in the composition is camphor.
A first embodiment of the present invention is to provide a composition in the form of a spray, liquid or nasal drops useful for treating respiratory diseases.
A second modality is the use of a terpenoid selected as camphor and the combination with active ingredients such as chlorobutanol or chloretone, menthol and essential oils.
The present invention also aims to provide a suitable combination of camphor and the
active ingredients that allow the deposition of the compounds in different sections of the respiratory tract by means of inhalers, drops, nebulizers or in liquid or spray form.
Camphor is a semisolid crystalline and waxy substance with a strong and pungent pungent odor. It is a terpenoid with the chemical formula CioHi60. It is found in the wood of the Alcanforero Cinnamomu camphora tree, and in some other trees of the lauraceae family. It can also be synthesized from turpentine oil. It is used as a balm and for other medicinal purposes.
Administered systemically, it has irritating and carminative properties, being used as a mild expectorant.
It has rubefaciente action, antipruritic, antiseptic and slightly analgesic. It is used in the form of liniments, alcoholic solutions and ointments, as a revulsant in joint pains, muscles, neuralgia and other similar conditions.
Administered systemically, it has irritating and carminative properties, being used as a mild expectorant.
Chemical structure of camphor:
-Alcanfor / (-) -Alcanfor
Chloretone (Chlorobutanol) its chemical formula is (C4H7CI30). It is mainly used as an antiseptic but also as a sedative, analgesic and fungicide.
Menthol is a saturated secondary alcohol, found in peppermint oils (Menta arvensis); It is a crystalline solid that melts around 40 C (104 F) and is used in medicine and in some cigarettes because it has a cooling effect on mucous membranes. It also has antipruritic and antiseptic properties. It is insoluble in water and soluble in alcohol and ether.
The cinnamon tree (Cinnamomum zeylanicum or Cinnamomum verum) is an evergreen tree. It is used as a spice for its internal bark, extracted by peeling and rubbing the branches and used in branch and ground. Its aroma is due to the aromatic essential oil that constitutes 0.5-2.5% of its composition. The major component is cinnamic aldehyde, also eugenol and cinnamic alcohol. With less proportion we find the trans-cinnamic acid, the hydroxycinnamic aldehyde, the o-methoxycinnamic aldehyde, cinnamic acetate, terpenes (linalool, diterpene), tannins,
mucilage, oligorameric proanthocyanidins, carbohydrates and traces of coumarin.
Eucalyptus or Eucalyptus (Eucalyptus) is a genus of trees (and some shrubs) of the Myrtaceae family. The young leaves of the eucalyptus contain an essential oil, with a characteristic balsamic odor, which is a powerful natural disinfectant and to fight respiratory infections. It is used in the form of ointment, tablets, syrups or sprays. The oil is used topically as a treatment for muscle and joint pain, as well as to treat cold sores.
In aromatherapy, it is used on the emotional side as a stimulant with a dissolving effect, and on the physical side as antiviral, expectorant and nasal.
Essential oils are mixtures of various chemical substances biosynthesized by plants, which give the characteristic aroma to some flowers, trees, fruits, herbs, spices, seeds and certain extracts of animal origin (musk, civet, ambergris). These are intensely aromatic, non-greasy chemicals (so they do not get rancid), volatile by nature (they evaporate quickly) and light (not very dense). They are insoluble in water, slightly soluble in vinegar, and soluble in alcohol, fats, waxes and vegetable oils. They are oxidized by exposure to air. More than 150 types have been extracted, each with its own aroma and unique healing virtues. They come from plants as common as parsley and as exquisite as jasmine. To give the best of themselves, they must come from raw natural ingredients and remain as pure as possible.
All the essential oils are antiseptic, but each one has its specific virtues, for example they can be analgesic, fungicides, diuretics or expectorants. The meeting of components of each oil also acts together to give the oil a key feature. It can be like chamomile, refreshing like grapefruit, stimulating like aromatic rosemary or soothing like cloves.
In the body, essential oils can act pharmacologically, physiologically and psychologically. They usually produce effects on various organs (especially the sense organs) and on various functions of the nervous system.
Mineral oil, this name is used for oils obtained by refining petroleum and whose use is that of lubricants. These oils stand out for their viscosity, their ability to lubricate against temperature and their ability to dissipate heat, as is the case with oils.
Petrolatum is a homogeneous mixture of long chain saturated hydrocarbons. Generally, chains of more than 25 carbon atoms, which are obtained from the refining of a heavy fraction of petroleum. The composition of said mixture may vary depending on the kind of oil and the refining process. The highly refined grade (white petrolatum) is used in the pharmaceutical and cosmetic industry, as a lubricant or as a base for the preparation of creams, respectively, and has a waxy, transparent whitish appearance.
To carry out the process of preparing the nasal composition for use against rhinitis, nasal allergy, sinusitis in the form of spray, drops or liquid were mixed at different proportions of camphor as terpenoid with active ingredients such as chloretone (chlorobutanol), menthol, Vaseline as mineral oil and / or almond oil as natural oil, cinnamon and eucalyptus in order to know the proper proportions of the compounds in the composition.
Examples
The following examples are intended to illustrate the invention, not to limit it, any variation by those skilled in the art, fall within the scope thereof.
Example 1
They were mixed in a container, 15% of camphor as terpenoid with 17% chloretone (chlorobutanol), 23% menthol, 31% almond oil as natural oil, 0.5% cinnamon and 13.5% eucalyptus as active ingredients. A homogeneous liquid composition was obtained by applying drops into the nasal cavities, acting as a lubricant and antihistaminic to decongest the nasal cavities. Fighting bacteria and microorganisms in the place where it was applied. The nasal composition acts with an effective protection time of 4 to 6 hours.
Example 2
They were mixed in a container, 15% of camphor as terpenoid with 17% chloretone (chlorobutanol), 23% menthol, 31% petrolatum oil as mineral oil, 0.5% cinnamon and 13.5% eucalyptus as active ingredients. A homogeneous liquid composition was obtained by applying drops into the nasal cavities, acting as a lubricant and antihistaminic to decongest the nasal cavities. Fighting bacteria and microorganisms in the place where it was applied. The nasal composition acts with an effective protection time of 4 to 6 hours.
Example 3
They were mixed in a container, 15% of camphor as terpenoid with 17% chloretone (chlorobutanol), 23% menthol, 31% almond oil as natural oil, 0.5% cinnamon and 13.5% eucalyptus as active ingredients. A homogeneous liquid composition was obtained by applying a spray inside the nasal cavities, acting as a lubricant and antihistamine to decongest the nasal cavities. Fighting bacteria and microorganisms in the place where it was applied. The nasal composition acts with an effective protection time of 4 to 6 hours. The smaller the particle size, the longer the particle will remain suspended in the air and the drug will be more effective.
Example 4
They were mixed in a container, 15% of camphor as terpenoid with 17% chloretone (chlorobutanol), 23% menthol, 31% almond oil as natural oil, 0.5% cinnamon and 13.5% eucalyptus as active ingredients. A homogeneous liquid composition was obtained by applying it in nebulization inside the nasal cavities, acting as a lubricant and antihistamine to decongest the nasal cavities. Fighting bacteria and microorganisms in the place where it was applied. The nasal composition acts with an effective protection time of 4 to 6 hours.
Example 5
They were mixed in a container, 15% of camphor as terpenoid with 17% chloretone (chlorobutanol), 23% menthol, 31% almond oil as natural oil, 0.5% cinnamon and 13.5% eucalyptus as active ingredients. A homogeneous liquid composition was obtained by applying a spray inside the nasal cavities, acting as a lubricant and antihistamine to decongest the nasal cavities. Fighting bacteria and microorganisms in the place where it was applied. The nasal composition acts with an effective protection time of 4 to 6 hours.
Example 6
They were mixed in a vessel, 15% of camphor as terpenoid with 17% chloretone (chlorobutanol), 23%. menthol, 31% almond oil as natural oil, 0.5% cinnamon and 13.5% eucalyptus as active ingredients. A homogenous composition was obtained applying in nebulization inside the nasal cavities acting as lubricant and antihistamine to decongest the nasal cavities. Fighting bacteria and microorganisms in the place where it was applied. The nasal composition acts with an effective protection time of 4 to 6 hours.
Example 7
They were mixed in a container, 15% of camphor as terpenoid with 17% chloretone (chlorobutanol), 23% menthol, 31% almond oil as natural oil, 0.5% cinnamon and 13.5% eucalyptus as active ingredients. A homogeneous liquid composition was obtained by applying it to facial towels and / or disposable tissues, acting as a lubricant and antihistamine to decongest the nasal cavities. Fighting bacteria and microorganisms in the place where it was applied. The nasal composition acts with an effective protection time of 4 to 6 hours.
Conclusions
It was concluded that the best results in terms of the improved composition of the present invention is the
composition in which the proportions are equal for each component ..
Table 1 shows the results obtained when treating 100 rhinitis patients with the composition of example 1 in drops, with respect to a drop composition only with chloretone, camphor and menthol in equal proportions, these drops (5 drops) were applied in the morning and afternoon for a week.
Table 1
As can be seen from the results in Table 1, we can conclude that the composition of Example 1 eliminates 100% the symptoms of rhinitis and the sensation of freshness and
nasal decongestant is better, than when using drops with cloretone, camphor and menthol only.
Additionally the improved nasal composition of the present invention when used as an adjuvant for rhinitis and / or rhinosinusitis is both chronic, allergic, atrophic, infectious both mycotic, viral and / or bacterial and is regularly used both for children in a dosage of
1 to 2 drops, for teens and adults the dosage is 2 to 4 drops 2 to 3 times a day.
If the improved nasal composition is used as a medication it is necessary to use it under medical prescription and if not its use will be according to the symptomatology and if there is no improvement consult your doctor.
It is noted that in relation to this date, the best method known to the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention.
Claims (14)
1. - An improved nasal composition with antihistaminic effect as a nasal decongestant characterized in that it comprises as active ingredients chloretone (chlorobutanol), menthol, mineral and / or natural oil, cinnamon, eucalyptus and a terpenoid of the formula: in which the radical R contains 60% Ci4, 30% Ci6, 5% Cí2 Y 5% Cl8 ·
2. - An improved nasal composition with antihistaminic effect as a nasal decongestant according to claim 1, characterized in that the terpenoid is selected from camphor.
3. - An improved nasal composition with antihistaminic effect as nasal decongestant according to claim 1, characterized in that the oil Mineral is selected from Vaseline natural oil selected from almond oil or mixtures thereof.
4. - An improved nasal composition with antihistamine effect as a nasal decongestant according to claim 1, characterized in that the chloretone (chlorobutanol) is in a proportion of 9 to 20%.
5. - An improved nasal composition with antihistamine effect as nasal decongestant according to claim 1, characterized in that menthol is in a proportion of 15 to 30%.
6. - An improved nasal composition with antihistamine effect as nasal decongestant according to claim 1, characterized in that the mineral and / or natural oil is in a proportion of 25 to 35%.
7. - An improved nasal composition with antihistamine effect as a nasal decongestant according to claim 1, characterized in that the camphor is in a proportion of 12 to 22%.
8. - An improved nasal composition with antihistamine effect as nasal decongestant according to claim 1, characterized in that the cinnamon is in a proportion of 0.001 to 2%.
9. - An improved nasal composition with antihistaminic effect as nasal decongestant according to claim 1, characterized in that the eucalyptus is in a proportion of 7 to 18%.
10. - An improved nasal composition with antihistaminic effect as a nasal decongestant according to claim 1, characterized in that the cinnamon is in the form of an essential oil.
11. - A nasal composition with an antihistaminic effect as a nasal decongestant according to claim 1, characterized in that the eucalyptus is in the form of an essential oil.
12. - The use of the improved composition of claim 1 for preparing a nasal composition in the form of drops with antihistaminic effect and as nasal decongestant to treat rhinitis, nasal allergy, sinusitis and other respiratory diseases.
13. - The use of the improved composition of claim 1 for preparing a composition in the form of spray, drops, and in liquid form, and in nebulization with antihistamine effect and as nasal decongestant to treat rhinitis, nasal allergy, sinusitis and other respiratory diseases.
14. - The use of the improved composition of claim 1 for preparing facial wipes, tissue paper towel or disposable handkerchief with antihistamine effect and as nasal decongestant to treat rhinitis, nasal allergy, sinusitis and others. respiratory diseases . Resume The present invention relates to an improved nasal composition for use against rhinitis, nasal allergy, sinusitis in the form of spray, drops or liquid. The composition of the present invention comprises a terpenoid, chloretone (chlorobutanol), menthol, mineral oil, cinnamon and eucalyptus. The terpenoid selected for use in the composition is camphor. The mineral oil is selected from petrolatum and / or natural oil is selected from almond oil and / or mixtures thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2012008419A MX347221B (en) | 2012-07-19 | 2012-07-19 | Improved composition based on terpenoids and chloretone, and the use thereof in nasal items. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2012008419A MX347221B (en) | 2012-07-19 | 2012-07-19 | Improved composition based on terpenoids and chloretone, and the use thereof in nasal items. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012008419A true MX2012008419A (en) | 2014-01-20 |
| MX347221B MX347221B (en) | 2017-04-20 |
Family
ID=50516246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012008419A MX347221B (en) | 2012-07-19 | 2012-07-19 | Improved composition based on terpenoids and chloretone, and the use thereof in nasal items. |
Country Status (1)
| Country | Link |
|---|---|
| MX (1) | MX347221B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104840520A (en) * | 2015-03-30 | 2015-08-19 | 李志君 | Rhinitis oil formula and preparation technology thereof |
| CN108126129A (en) * | 2018-02-10 | 2018-06-08 | 鄂尔多斯市蔚蓝生物科技有限公司 | A kind of nasil preparation for being used to treat rhinitis |
-
2012
- 2012-07-19 MX MX2012008419A patent/MX347221B/en active IP Right Grant
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104840520A (en) * | 2015-03-30 | 2015-08-19 | 李志君 | Rhinitis oil formula and preparation technology thereof |
| CN108126129A (en) * | 2018-02-10 | 2018-06-08 | 鄂尔多斯市蔚蓝生物科技有限公司 | A kind of nasil preparation for being used to treat rhinitis |
Also Published As
| Publication number | Publication date |
|---|---|
| MX347221B (en) | 2017-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bhowmik et al. | Recent trends in Indian traditional herbs Syzygium aromaticum and its health benefits | |
| CN102429840B (en) | Mosquito repellent and preparation method thereof | |
| Singh et al. | Cinnamomum camphora (Kapur) | |
| Manganelli et al. | Ethnopharmacobotanical studies of the Tuscan Archipelago | |
| Singh et al. | Eugenia caryophyllata Thunberg (family myrtaceae): a review | |
| US20060222723A1 (en) | Terpene-based composition of substances, a method for its preparation and a method for its dispersal into the atmosphere | |
| US20110150995A1 (en) | Solid Dosage Forms of Essential Oils | |
| US20090191249A1 (en) | Sheet substrates impregnated with aromatic releasing compositions and a method of delivery of aromatic releasing compositions | |
| CN105340998A (en) | Natural traditional Chinese medicine mosquito-repellent incense and preparation method thereof | |
| CHALANNAVAR | Role of botanical essential oils as a therapy for controlling coronavirus (SARS-CoV-2) disease (Covid-19) | |
| CN112075459A (en) | Antiviral and antibacterial respiratory tract compound essential oil and preparation method thereof | |
| CN114246925A (en) | Traditional Chinese medicine essential oil and application thereof | |
| KR20030019097A (en) | Compositions for treatment and prevention of cold having antiviral activity | |
| EP2533790A2 (en) | Composition for the treatment and prevention of anxiety disorders and dyssomnia | |
| CN103263679B (en) | The preparation method of the fragrant plant air scavenging solution of medicine of environment purification, strengthening respiratory system | |
| Yadav et al. | Ethnopharmacology and traditional attributes of clove (Syzygium aromaticum) | |
| MX2012008419A (en) | Improved composition based on terpenoids and chloretone, and the use thereof in nasal items. | |
| CN104758322A (en) | Composition capable of expelling insects, killing bacteria, sterilizing, and relieving nerve, and applications thereof | |
| Ahmad et al. | Herbo-medicinal formulation; Marham-e-raal: A potent ointment for acute and chronic wounds–A review | |
| CA2357106A1 (en) | Aromatherapeutic environmental system | |
| CN106336730A (en) | An environmentally friendly water-based black ink | |
| CN112704697A (en) | Atomized liquid for resisting epidemic and maintaining respiratory tract health and preparation method thereof | |
| Akbar | Santalum album L.(Santalaceae) | |
| Mounika et al. | Invitro evaluation of antimicrobial activity of Clove buds (Euginea aromatica) | |
| US20040146587A1 (en) | Topical composition for relief of pain and minor skin irritations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |